Antibodies are critical components of our immune system. We have all heard how if we are infected with the coronavirus or are immunized, we will develop antibodies that will fight the infection. This is because antibodies have the unique ability to recognize any other protein, human or viral, with great specificity. Scientists take advantage of this property to generate antibodies for research, as they can recognize proteins from complex mixtures of proteins such as those found in a human cell. Companies make antibodies and sell them to scientists but determining which of these antibodies is appropriate for any given scientific application is challenging, for the companies and the scientist. This leads to use of non-specific antibodies that waste public funds and contributes to issues with scientific reproducibility. We are developing a third-party antibody characterization entity that uses standardized operating procedures to assess and compare antibody performance. We cooperate with multiple antibody manufacturing companies and compare all antibodies from all companies against any given protein target in a head-to-head comparison following the principles of open science, such that all data is released to the public domain without bias. This unique model will enhance the reproducibility of scientific data.
Lead Genome Centre: Génome Québec
User :
| Chetan | Raina | YCharOS Inc |